Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Sponsor: National Institute of Mental Health (NIMH)
Listed as NCT00000392, this PHASE2 trial focuses on Cognition Disorders and HIV Infections and remains completed. Sponsored by National Institute of Mental Health (NIMH), it has been updated 7 times since 1990, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jan 1990
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Mental Health (NIMH)
For direct contact, visit the study record on ClinicalTrials.gov .